- Home
- QFIN vs GH Comparison
QFIN vs GH Comparison
Compare QFIN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QFIN
- GH
- Stock Information
- Founded
- QFIN 2016
- GH 2011
- Country
- QFIN China
- GH United States
- Employees
- QFIN N/A
- GH N/A
- Industry
- QFIN Finance: Consumer Services
- GH Medical Specialities
- Sector
- QFIN Finance
- GH Health Care
- Exchange
- QFIN Nasdaq
- GH Nasdaq
- Market Cap
- QFIN 3.9B
- GH 3.0B
- IPO Year
- QFIN 2018
- GH 2018
- Fundamental
- Price
- QFIN $24.97
- GH $26.25
- Analyst Decision
- QFIN Strong Buy
- GH Strong Buy
- Analyst Count
- QFIN 1
- GH 17
- Target Price
- QFIN $23.80
- GH $39.31
- AVG Volume (30 Days)
- QFIN 1.8M
- GH 2.3M
- Earning Date
- QFIN 08-13-2024
- GH 11-04-2024
- Dividend Yield
- QFIN 4.73%
- GH N/A
- EPS Growth
- QFIN 25.79
- GH N/A
- EPS
- QFIN 4.12
- GH N/A
- Revenue
- QFIN $2,351,728,381.00
- GH $643,810,000.00
- Revenue This Year
- QFIN $4.14
- GH $27.01
- Revenue Next Year
- QFIN $3.31
- GH $18.30
- P/E Ratio
- QFIN $6.12
- GH N/A
- Revenue Growth
- QFIN 9.80
- GH 26.20
- 52 Week Low
- QFIN $13.68
- GH $15.81
- 52 Week High
- QFIN $26.50
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- QFIN 60.44
- GH 47.12
- Support Level
- QFIN $24.30
- GH $24.55
- Resistance Level
- QFIN $25.39
- GH $25.87
- Average True Range (ATR)
- QFIN 0.70
- GH 1.13
- MACD
- QFIN -0.23
- GH 0.18
- Stochastic Oscillator
- QFIN 34.09
- GH 69.88
About QFIN Qifu Technology Inc.
Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.